This report provides the current prevalent population for AATD across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the publisher's analysis team, AATD patients grouped by comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of AATD include:
Cirrhosis
COPD
Lung Cancer
Asthma
Panniculitis
Systemic Vasculitis
Reasons to buy
Ability to quantify patient populations in global AATD market to target the development of future products, pricing strategies and launch plans.
Further insight into the prevalence of the subdivided types of AATD and identification of patient segments with high potential.
Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
Better understanding of the impact of specific co-morbid conditions on the prevalent population of AATD patients.
Identification of AATD patient sub-populations that require treatment.
Better understanding of the specific markets that have the largest number of AATD patients.
Key Topics Covered:
List Of Tables And Figures
Introduction
Cause Of The Disease
Risk Factors & Prevention
Diagnosis Of The Disease
Variation By Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Comorbid Conditions / Features Associated With The Disease
Methodology For Quantification Of Patient Numbers
Top-Line Prevalence For Alpha-1 Anti-Trypsin Deficiency
Comorbidities Of Alpha-1 Anti-Trypsin Deficiency Patients
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Pharma Parenteral Packaging Market ? By Drug Type (Small Molecules, Biologics, Vaccines, Biosimilars, & Others), By Product Type (Bottles, Ampoules,...
Thermo Fisher Scientific Inc. , the world leader in serving science, will hold its 2024 Investor Day on Thursday, September 19, starting at 9:00 a.m. (ET) in New York City.
The format will feature presentations by members of Thermo Fisher...
Thermo Fisher Scientific Inc. , the world leader in serving science, today reported its financial results for the first quarter ended March 30, 2024.
First Quarter 2024 Highlights
First quarter revenue was $10.34 billion.
First quarter GAAP...
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, announced today that it will release financial results for the first quarter ended March 31, 2024 after the close of trading on Wednesday, May 8. Biodesix's...
Revvity, Inc. today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test. The Auto-Pure 2400 platform is easy to use and designed to provide efficient workflows in the lab. When the accuracy of the...